Archives
-
Clusterin, Oxidative Stress, and UC Barrier Injury
2026-10-06
The reference study links reduced clusterin expression with more severe ulcerative colitis and identifies mitochondrial dysfunction, epithelial barrier disruption, and impaired Keap1–Nrf2 antioxidant signaling as connected features of oxidative injury. Its strength is the integration of patient observations, a mouse colitis model, and epithelial-cell perturbation, while its translational relevance remains limited by model dependence and the absence of clinical intervention data.
-
7-Ethyl-10-hydroxycamptothecin: Evidence Guide
2026-10-06
7-Ethyl-10-hydroxycamptothecin, also known as SN-38, is an active irinotecan metabolite and DNA topoisomerase I inhibitor. Evidence supports canonical topoisomerase I poisoning and a reported FUBP1–FUSE transcriptional mechanism, while vendor-reported colon cancer findings require careful separation from peer-reviewed HCC evidence.
-
Jasplakinolide as a Mechanistic Probe of Actin
2026-10-05
Jasplakinolide is an actin polymerization inducer that can reveal how cytoskeletal state shapes cellular behavior. This article develops an evidence-centered framework for interpreting direct F-actin effects, downstream phenotypes, and chemical-genetic insights without confusing perturbation with mechanism.
-
SIRT1, Vascular Coupling, and Bone Aging
2026-10-05
Liu et al. show that SIRT1 supports both endothelial activity and osteogenic differentiation in aged bone models, linking vascular–osteogenic coupling to β-catenin deacetylation and Wnt signaling. The findings provide a mechanistic framework for studying skeletal regeneration, while the model scope and pharmacological design limit direct translation to human osteoporosis.
-
EX 527: Reading SIRT1 in Aging Bone
2026-10-04
EX 527 (SEN0014196) offers a selective way to interrogate whether SIRT1 catalytic activity contributes to vascular–osteogenic coordination in aging bone. This article explains how to interpret inhibitor-based evidence alongside Liu et al.’s findings on β-catenin, type H vessels, and skeletal regeneration.
-
Apicidin Disrupts Oocyte Meiosis and Acetylation
2026-10-03
A 2026 study identifies a previously undercharacterized reproductive-toxicity profile for Apicidin, showing that exposure compromises oocyte meiotic maturation, spindle organization, chromosome alignment, actin structure, and selected acetylation markers. The findings connect HDAC-associated molecular changes with oocyte-quality defects, while remaining limited to an in vitro model and not establishing human fertility risk or direct causality.
-
IDO1 Inhibition and Tumor-Intrinsic STAT3
2026-10-02
The reference study shows that apo-IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2/STAT3 survival response within tumor cells. Its single-cell analysis provides a mechanistic explanation for why immune activation alone may not translate into therapeutic benefit and supports testing IDO1 inhibition with pathway-directed combinations.
-
EX 527: A Causal Map of SIRT1 in Bone Aging
2026-10-01
EX 527 (SEN0014196) enables a causal, mechanism-focused analysis of SIRT1 in aged bone models. This article connects biochemical target engagement with p53 acetylation, vascular–osteogenic coupling, and β-catenin signaling while defining practical assay controls and interpretation limits.
-
Network Medicine Identifies Apigenin for Alzheimer’s
2026-10-01
Ding and colleagues used network proximity analysis to prioritize flavonoids with potential activity against Alzheimer’s disease targets, then validated the leading candidates in neuronal and microglial models. Apigenin showed the strongest profile among the tested compounds, linking mitochondrial preservation, reduced apoptosis, AKT/NF-κB modulation, and microglial-state regulation.
-
Belinostat (PXD101) Workflow for HDAC Research
2026-09-30
Belinostat (PXD101) combines broad histone deacetylase inhibition with measurable chromatin, cell-cycle, and growth phenotypes, making it useful for integrated cancer biology workflows. This guide connects its benchmark activity in bladder and prostate models with a carefully bounded strategy for studying acetylation-dependent splicing and PARP-inhibitor response in HCC.
-
M344 Histone Deacetylase Inhibitor Workflows
2026-09-30
M344 connects HDAC inhibition with measurable changes in cancer-cell growth, differentiation, radiation response, and viral latency. This practical guide turns those use cases into dose-ranging workflows, assay choices, and troubleshooting checkpoints for reproducible in vitro research.
-
Nonivamide: A TRPV1 Assay Decision Framework
2026-09-29
Nonivamide is a capsaicin analog that connects TRPV1 activation with cancer cell growth inhibition and neuroimmune assay design. This guide distinguishes direct tumor-cell apoptosis from host somato-autonomic effects and translates both evidence streams into better experimental decisions.
-
RIPostC, Ketone Bodies, and Ferroptosis After Stroke
2026-09-29
A 2024 ACS Chemical Neuroscience study identifies ketone-body metabolism as a mechanistic link between remote ischemic postconditioning and neuroprotection after experimental stroke. By combining rat middle cerebral artery occlusion with oxygen-glucose deprivation/reoxygenation studies, the authors connect improved energy metabolism with reduced ferroptosis, preserved GPX4, lower ACSL4 and iron burden, and improved neuronal outcomes.
-
LY364947: TGF-β Type I Receptor Workflows
2026-09-28
LY364947 provides a focused way to test how TGF-β receptor kinase activity controls Smad2 phosphorylation, EMT, fibrosis-associated phenotypes, and tissue injury responses. This workflow-oriented guide connects pathway inhibition with orthogonal readouts and the Wnt/β-catenin–TGF-β crosstalk highlighted in recent pancreatic cancer research.
-
Regulated Cell Death Mechanisms in Heart Disease
2026-09-28
Konstantinidis, Whelan, and Kitsis synthesize evidence that both apoptosis and a meaningful subset of necrotic cell deaths are regulated processes in myocardial infarction and heart failure. Their review emphasizes overlapping death pathways and the need to distinguish cell-death modes using multiple biological readouts, while noting that pathway relationships and therapeutic implications remain unsettled.